External radiotherapy for prostatic cancers

Mottet, 2021, EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent, Eur Urol, 79, 243, 10.1016/j.eururo.2020.09.042

2020

Rozet, 2020, [French ccAFU guidelines - update 2020-2022: prostate cancer], Prog Urol, 30, S136, 10.1016/S1166-7087(20)30752-1

D’Amico, 1998, Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, JAMA, 280, 969, 10.1001/jama.280.11.969

Zumsteg, 2013, A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy, Eur Urol, 64, 895, 10.1016/j.eururo.2013.03.033

Bolla, 2002, Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial, Lancet, 360, 103, 10.1016/S0140-6736(02)09408-4

Hamdy, 2016, 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer, N Engl J Med, 375, 1415, 10.1056/NEJMoa1606220

Dayes, 2017, Long-term results of a randomized trial comparing iridium implant plus external beam radiation therapy with external beam radiation therapy alone in node-negative locally advanced cancer of the prostate, Int J Radiat Oncol Biol Phys, 99, 90, 10.1016/j.ijrobp.2017.05.013

Hoskin, 2021, Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: mature 12-year results, Radiother Oncol, 154, 214, 10.1016/j.radonc.2020.09.047

Rodda, 2017, ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer, Int J Radiat Oncol Biol Phys, 98, 286, 10.1016/j.ijrobp.2017.01.008

Rodda, 2017, ASCENDE-RT: an analysis of health-related quality of life for a randomized trial comparing low-dose-rate brachytherapy boost with dose-escalated external beam boost for high- and intermediate-risk prostate cancer, Int J Radiat Oncol Biol Phys, 98, 581, 10.1016/j.ijrobp.2017.02.027

Morris, 2017, Int J Radiat Oncol Biol Phys, 98, 275, 10.1016/j.ijrobp.2016.11.026

Amini, 2016, Survival outcomes of dose-escalated external beam radiotherapy versus combined brachytherapy for intermediate and high risk prostate cancer using the national cancer data base, J Urol, 195, 1453, 10.1016/j.juro.2015.11.005

Spratt, 2021, Prostate radiotherapy with adjuvant androgen deprivation therapy (ADT) improves metastasis-free survival compared to neoadjuvant ADT: an individual patient meta-analysis, J Clin Oncol, 39, 136, 10.1200/JCO.20.02438

Boeve, 2019, Eur Urol, 75, 410, 10.1016/j.eururo.2018.09.008

Parker, 2018, Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial, Lancet, 392, 2353, 10.1016/S0140-6736(18)32486-3

Ali, 2021, Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial, JAMA Oncol, 7, 555, 10.1001/jamaoncol.2020.7857

Cornford, 2021, EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. part II-2020 update: treatment of relapsing and metastatic prostate cancer, Eur Urol, 79, 263, 10.1016/j.eururo.2020.09.046

Lieng, 2018, Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group, Radiother Oncol, 129, 377, 10.1016/j.radonc.2018.06.027

Hennequin, 2010, [Prostate cancer: doses and volumes of radiotherapy], Cancer Radiother, 14, 474, 10.1016/j.canrad.2010.07.229

Eifler, 2013, An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011, BJU Int, 111, 22, 10.1111/j.1464-410X.2012.11324.x

Pommier, 2007, Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01, J Clin Oncol, 25, 5366, 10.1200/JCO.2006.10.5171

Roach, 2006, Whole-pelvis, “mini-pelvis,” or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial, Int J Radiat Oncol Biol Phys, 66, 647, 10.1016/j.ijrobp.2006.05.074

Chapet, 2013, [Pelvic irradiation in prostate cancer: what place for what volumes?.], Cancer Radiother, 17, 562, 10.1016/j.canrad.2013.07.133

Murthy, 2021, Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial, J Clin Oncol, 39, 1234, 10.1200/JCO.20.03282

Brand, 2019, Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial, Lancet Oncol, 20, 1531, 10.1016/S1470-2045(19)30569-8

Kalbasi, 2015, Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer, JAMA Oncol, 1, 897, 10.1001/jamaoncol.2015.2316

Beckendorf, 2011, 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of Gétug 06 randomized trial, Int J Radiat Oncol Biol Phys, 80, 1056, 10.1016/j.ijrobp.2010.03.049

de Vries, 2020, Hyprofractionated versus conventionally fractionated radiation therapy for patients with intermediate- or high-risk, localized, prostate cancer: 7-year outcomes from the randomized, multicenter, open-label, phase 3 HYPRO trial, Int J Radiat Oncol Biol Phys, 106, 108, 10.1016/j.ijrobp.2019.09.007

Martin, 2018, Moderately hypofractionated prostate external-beam radiotherapy: an emerging standard, Br J Radiol, 20170807, 10.1259/bjr.20170807

Bruner, 2019, Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial, JAMA Oncol, 5, 664, 10.1001/jamaoncol.2018.6752

Catton, 2017, Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer, J Clin Oncol, 35, 1884, 10.1200/JCO.2016.71.7397

Dearnaley, 2016, Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial, Lancet Oncol, 17, 1047, 10.1016/S1470-2045(16)30102-4

Lee, 2016, Randomized phase III Noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer, J Clin Oncol, 34, 2325, 10.1200/JCO.2016.67.0448

Line Krhili, 2019, [Moderate or extreme hypofractionation and localized prostate cancer: The times are changing], Cancer Radiother, 23, 503, 10.1016/j.canrad.2019.07.139

Cheung, 2020, Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localised prostate cancer: ready for prime time?, Clin Oncol (R Coll Radiol), 32, 181, 10.1016/j.clon.2019.12.002

Faria, 2017, Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy, Practical radiation oncology, 7, 264, 10.1016/j.prro.2017.01.003

Jackson, 2019, Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies, Int J Radiat Oncol Biol Phys, 104, 778, 10.1016/j.ijrobp.2019.03.051

Fransson, 2021, Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial, Lancet Oncol, 22, 235, 10.1016/S1470-2045(20)30581-7

Widmark, 2019, Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial, Lancet, 394, 385, 10.1016/S0140-6736(19)31131-6

Sargos, 2015, Definition of lymph node areas for radiotherapy of prostate cancer: A critical literature review by the French Genito-Urinary Group and the French Association of Urology (Gétug-Afu), Cancer Treat Rev, 41, 814, 10.1016/j.ctrv.2015.10.005

Gay, 2012, Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas, Int J Radiat Oncol Biol Phys, 83, e353, 10.1016/j.ijrobp.2012.01.023

Hall, 2021, NRG Oncology updated international consensus atlas on pelvic lymph node volumes for intact and postoperative prostate cancer, Int J Radiat Oncol Biol Phys, 109, 174, 10.1016/j.ijrobp.2020.08.034

Luo, 2006, Use of benchmark dose-volume histograms for selection of the optimal technique between three-dimensional conformal radiation therapy and intensity-modulated radiation therapy in prostate cancer, Int J Radiat Oncol Biol Phys, 66, 1253, 10.1016/j.ijrobp.2006.06.010

Wang-Chesebro, 2006, Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer, Int J Radiat Oncol Biol Phys, 66, 654, 10.1016/j.ijrobp.2006.05.037

Spratt, 2013, Long-term survival and toxicity in patients with high-dose intensity modulated radiation therapy for localized prostate cancer, Int J Radiat Oncol Biol Phys, 85, 686, 10.1016/j.ijrobp.2012.05.023

Cahlon, 2008, Intensity-modulated radiation therapy: supportive data for prostate cancer, Seminars in radiation oncology, 18, 48, 10.1016/j.semradonc.2007.09.007

Quan, 2012, A comprehennsive comparison of IMRT and VMAT plan quality for prostate cancer treatment, Int J Radiat Oncol Biol Phys, 83, 1169, 10.1016/j.ijrobp.2011.09.015

Fiorino, 2009, Dose–volume effects for normal tissues in external radiotherapy: pelvis, Radiother Oncol, 93, 153, 10.1016/j.radonc.2009.08.004

Marks, 2010, Use of normal tissue complication probability models in the clinic, Int J Radiat Oncol Biol Phys, 76, S10, 10.1016/j.ijrobp.2009.07.1754

Langrand-Escure, 2018, Dose constraints for moderate hypofractionated radiotherapy for prostate cancer: The French genito-urinary group (Gétug) recommendations, Cancer Radiother, 22, 193, 10.1016/j.canrad.2017.11.004

Lapierre, 2019, [Stereotactic ablative body radiotherapy: which machine for which therapeutic indication? A focus on prostate cancer], Cancer Radiother, 23, 651, 10.1016/j.canrad.2019.06.009

Pasquier, 2019, GETUG-AFU 31: a phase I/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy-study protocol, BMJ Open, 9, e026666, 10.1136/bmjopen-2018-026666

Pasquier, 2019, Salvage stereotactic body radiation therapy for local prostate cancer recurrence after radiation therapy: a retrospective multicenter study of the Gétug, Int J Radiat Oncol Biol Phys, 105, 727, 10.1016/j.ijrobp.2019.07.012

Ghadjar, 2019, ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer, Radiother Oncol, 141, 5, 10.1016/j.radonc.2019.08.027

Sargos, 2020, Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (Gétug-Afu 17): a randomised, phase 3 trial, Lancet Oncol, 21, 1341, 10.1016/S1470-2045(20)30454-X

Abdollah, 2018, Impact of adjuvant radiotherapy in node-positive prostate cancer patients: the importance of patient selection, Eur Urol, 74, 253, 10.1016/j.eururo.2018.04.017

Carrie, 2016, Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (Gétug-Afu 16): a randomised, multicentre, open-label phase 3 trial, Lancet Oncol, 17, 747, 10.1016/S1470-2045(16)00111-X

Poortmans, 2007, Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group, Radiother Oncol, 84, 121, 10.1016/j.radonc.2007.07.017

Michalski, 2010, Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer, Int J Radiat Oncol Biol Phys, 76, 361, 10.1016/j.ijrobp.2009.02.006

Sidhom, 2008, Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group, Radiother Oncol, 88, 10, 10.1016/j.radonc.2008.05.006

Wiltshire, 2007, Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy, Int J Radiat Oncol Biol Phys, 69, 1090, 10.1016/j.ijrobp.2007.04.068

Robin, 2021, Prostate bed delineation guidelines for postoperative radiation therapy: on behalf of the francophone group of urological radiation therapy, Int J Radiat Oncol Biol Phys, 109, 1243, 10.1016/j.ijrobp.2020.11.010

Vilotte, 2017, Post-prostatectomy image-guided radiotherapy: the invisible target concept, Front Oncol, 7, 34, 10.3389/fonc.2017.00034

Pommier, 2022, Prostate cancer brachytherapy: SFRO guidelines 2021, Cancer Radiother, 26, 10.1016/j.canrad.2021.11.019